Q2 FY2026 EarningsQ2 FY2026 missed consensus on GAAP EPS, reporting -$2.80 vs. -$1.92 expected, primarily due to a $5.1M non-cash asset impairment charge. Revenue was in-line at $0, consistent with its clinical-stage status. The company announced a transformative merger with Avere Therapeutics and a substantial workforce reduction, shifting focus away from legacy oncology assets SIM0505 and LNCB74.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: NextCure(NXTC) the EBIT is -15.09 M (+44.69%), Miss estimate;the EPS is -2.8 (+75.2%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITMiss expectations
-0.02B44.69%
-0.01B61.80%
-0.00B17.11%
EPSMiss expectations
-2.875.20%
-1.922582.97%
-0.87757.77%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf